Quest for Clinically Effective RAF Dimer Inhibitors-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Quest for Clinically Effective RAF Dimer Inhibitors

Published:2020-07-01 Issue:19 Volume:38 Page:2197-2200
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Xue Jenny Y.¹²,Lito Piro¹³⁴

Affiliation:

1. Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY

2. Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-PhD Program, New York, NY

3. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

4. Department of Medicine, Weill Cornell Medical College, New York, NY

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.20.00401

Reference33 articles.

1. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

2. Tumor adaptation and resistance to RAF inhibitors

3. Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

4. Regulation of RAF protein kinases in ERK signalling

5. New perspectives for targeting RAF kinase in human cancer

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Trends in Treatment and New Generation of Trials in Thyroid Cancer;Practical Management of Thyroid Cancer;2023

2. RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeutics;Journal of Clinical Investigation;2021-11-15

3. Adult pilocytic astrocytoma in the molecular era: a comprehensive review;CNS Oncology;2021-03-01

4. A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker;Current Oncology;2020-12-25

5. Inhibitors of BRAF dimers using an allosteric site;Nature Communications;2020-09-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3